2-[(4-氯苯基)甲基氨基]乙酸 | 114479-33-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-[(4-氯苯基)甲基氨基]乙酸
• 英文名称: N-<4-Chlor-benzyl>-glycin
• 英文别名: 2-(4-chlorobenzylamino)acetic acid；2-[(4-chlorophenyl)methylazaniumyl]acetate
• CAS: 114479-33-3
• 化学式: C₉H₁₀ClNO₂
• mdl: MFCD03450369
• 分子量: 199.637
• InChiKey: AEUCLXJGFMJQMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  2-[(4-氯苯基)甲基氨基]乙酸 在 盐酸 、 乙酸酐 、 sodium nitrite 作用下， 生成 3-(4-chloro-benzyl)-sydnone
  参考文献：
  名称：

  Greco,C.V. et al., Journal of medicinal and pharmaceutical chemistry, 1962, vol. 5, p. 861 - 865

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(4-氯苄基氨基)乙酸乙酯 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 2-[(4-氯苯基)甲基氨基]乙酸
  参考文献：
  名称：

  Design of Selective Peptidomimetic Agonists for the Human Orphan Receptor BRS-3

  摘要：

  New tool substances may help to unravel the physiological role of the human orphan receptor BRS-3 and its possible use as a drug target for the treatment of obesity and cancer. In continuation of our work on BRS-3, the solid- and solution-phase synthesis of a library of low molecular weight peptidomimetic agonists based on the recently developed short peptide agonist 4 is described. Functional potencies of the compounds were determined measuring calcium mobilization in a fluorometric imaging plate reader (FLIPR) assay. Focusing on the N-terminus, the D-Phe-Gln moiety of 4 was modified in a combinatorial. SAR-oriented medicinal chemistry approach. With the incorporation of N-arylated glycine and alanine building blocks azaglycine, piperazine, or piperidine and the synthesis of semicarbazides and semicarbazones, a number of highly potent and selective compounds with a reduced number of peptide bonds were obtained, which also should have enhanced metabolic stability.

  DOI：

  10.1021/jm0210921

文献信息

• [EN] SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS<br/>[FR] COMPOSÉS DE SULFONAMIDE ET LEUR UTILISATION COMME INHIBITEURS DE STAT5
  申请人：UNIV TORONTO

  公开号：WO2015179956A1

  公开（公告）日：2015-12-03

  The present disclosure relates to compounds having the Formula (Formula (I)) which are inhibitors of STAT5.

  本公开涉及具有化学式（化学式（I））的化合物，这些化合物是STAT5的抑制剂。
• HDAC Inhibitors as Anti-Cancer Agents
  申请人：The University of Toledo

  公开号：US20150329560A1

  公开（公告）日：2015-11-19

  Largazole analogues, methods of making the same, and methods of using the same, are described.

  Largazole类似物，其制备方法和使用方法被描述。
• 1,2,3-Triazole-boranes: stable and efficient reagents for ketone and aldehyde reductive amination in organic solvents or in water
  作者：Wenyan Liao、Yunfeng Chen、Yuxiu Liu、Haifeng Duan、Jeffrey L. Petersen、Xiaodong Shi

  DOI：10.1039/b915361f

  日期：——

  Air, moisture and thermally stable 1,2,3-triazole-borane complexes were developed as new practical reagents for ketone/aldehyde amination with high efficiency and excellent substrate diversity.

  空气，水分和热稳定的1,2,3-三唑-硼烷配合物被开发为高效/高效的酮/醛胺化的新型实用试剂，并且具有出色的底物多样性。
• METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION
  申请人：Neubig Richard

  公开号：US20120252792A1

  公开（公告）日：2012-10-04

  The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.

  本发明提供了抑制Rho GTPase家族成员的方法、组合物和试剂盒。具体来说，本发明提供了抑制RhoA和/或RhoC转录信号的方法、组合物和试剂盒。本发明可用于治疗Rho介导的疾病状态（例如肿瘤转移、炎症、炎症性疾病）、Rho介导的生物条件以及细胞信号研究。
• BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE
  申请人：Fujita Takashi

  公开号：US20130165446A1

  公开（公告）日：2013-06-27

  The present invention addresses the problem of finding a compound having both PPAR activation activity and angiotensin receptor antagonistic activity. The present invention is a benzo- or pyrido-imidazole derivative represented by general formula (I), a pharmaceutically acceptable salt thereof, or a ester or amide thereof (where A is biphenyl methyl-imidazolyl, biphenyl methyl-benzimidazolyl, or the like, B is divalent benzimidazolyl or the like, C is carboxyl or the like, E is divalent phenyl, naphthyl, or the like, G is a dangling bond, oxygen, or the like, Q is oxygen or sulfur, n is an integer from 1 to 6, p is an integer from 1 to 6, V is a dangling bond, oxygen, or the like, and R is hydrogen, alkyl, or the like).

  本发明解决了寻找既具有PPAR激活活性又具有血管紧张素受体拮抗活性的化合物的问题。本发明是一种由通式（I）表示的苯并或吡啶-咪唑衍生物，其药学上可接受的盐，或其酯或酰胺（其中A是联苯甲基咪唑基，联苯甲基苯并咪唑基或类似物，B是二价苯并咪唑基或类似物，C是羧基或类似物，E是二价苯基，萘基或类似物，G是悬键，氧或类似物，Q是氧或硫，n是从1到6的整数，p是从1到6的整数，V是悬键，氧或类似物，R是氢，烷基或类似物）。